The Summary of TERLIVAZ&reg; (terlipressin): the first FDA-approved treatment for HRS in adults with rapid reduction in kidney function. TLM theater will highlight the importance of early recognition and current diagnosis and treatment recommendations for hepatorenal syndrome&ndash;acute kidney injury (HRS-AKI).<br />
<br />
Industry Supporter:&nbsp;Mallinckrodt Pharmaceuticals

National Cancer Institute program staff will discuss current funding opportunities for basic and clinical research at the National Cancer Institute and take questions regarding the grant process and funding opportunities.

How do you study palliative care? Come discuss the science behind the recent Hepatology Communications article on the &ldquo;Surprise Question,&rdquo; a clinician-based prognostication tool initially developed to identify patients who may benefit from palliative care interventions with Dr. Nneka Ufere. Read the article here:&nbsp;<a href="https://journals.lww.com/hepcomm/fulltext/2025/08010/accuracy_of_the__s… />
&nbsp;<br />
12:45-12:55 PM- Presentation<br />
12:55-1:15 PM- Audience Q&amp;A and Discussion<br />
&nbsp;

In this session, investigators will present cutting-edge clinical studies on transplant and discoveries from consortia and registries.

Late-Breaking Abstract Parallel sessions feature oral presentations from the authors of cutting-edge, highly-rated abstracts submitted for presentation at The Liver Meeting.

Have questions about ScholarOne or technical questions about submitting to Hepatology, Liver Transplantation, or Hepatology Communications? Come ask our Editorial Office staff!<br />
Friday, Nov 7 and Monday, Nov 10 at 9:45 AM- 10:15 AM<br />
AASLD Publications Staff: <a href="mailto:hepatology@aasld.org">hepatology@aasld.org</a&gt;, <a href="mailto:livertransplantation@aasld.org">livertransplantation@aasld.org</…;, <a href="mailto:hepcomm@aasld.org">hepcomm@aasld.org</a><br />
&nbsp;